Investor Presentation First Nine Months of 2022
71
Investor presentation First nine months of 2022
Novo NordiskⓇ
The phase 3a OASIS trial investigating oral semaglutide 50 mg in
obesity initiated in Q3 2021 and expected to complete in H1 2023
Global trial planned was started in H2 2021
Plan to include 660 patients with obesity
Objective
To investigate superiority of oral semaglutide 50 mg vs. placebo on
weight loss in people with overweight or obesity
Oral semaglutide 50 mg
R
1:1
Placebo oral
Primary endpoint
•
Change in body weight from baseline (%)
.
Body weight reduction ≥ 5%
68 weeks
7 weeks
follow-up
OASIS programme scope
Inclusion criteria
• BMI: ≥27 kg/m² with ≥ 1 weight-related comorbidity, or
• BMI ≥30 kg/m²
Weight-related comorbidities are hypertension, dyslipidaemia,
obstructive sleep apnoea and CVD
OASIS: Oral Semaglutide treatment effect In people with Obesity; CVD: Cardiovascular disease; BMI: Body Mass Index
Total of 1,000 patients across three trials: 1) A global (North
America and Europe), 2) Japanese and 3) Chinese trialView entire presentation